Steve Profit – General Manager, Novo Nordisk Taiwan
Steve Profit, general manager of Novo Nordisk Taiwan, shares a newcomers’ perspective as a recent transplant to the market from the company’s global office in Denmark. Profit goes on to…
Address: 7F-1, No.216, Sec.2, Tun Hua South Road, Taipei 106, Taiwan
,Taiwan
Tel: (02)2377-2566
Web: http://www.novonordisk.com.tw/documents/home_page/document/index.asp
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk Taiwan received several awards from patients associations, mainly for supporting those organisations’ activities such as diabetes patients’ camps or patients’ clubs via booth or speech programs. Novo Nordisk Taiwan received an award from Taiwan Diabetes Association for special dedication and contribution during World Diabetes Day 2007.
Pharmaceuticals
Steve Profit, general manager of Novo Nordisk Taiwan, shares a newcomers’ perspective as a recent transplant to the market from the company’s global office in Denmark. Profit goes on to…
Novo Nordisk is one of the few pharmaceutical multinationals focused in one key therapeutic area. Perhaps you could start by telling our readers about how diabetes has evolved in Taiwan…
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry…
Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent…
Dr Yu-Ray Chen, Professor of Surgery at Chang Gung Memorial Hospital discusses the current state of Taiwan’s healthcare system, highlighting the fact that its current condition is unsustainable in the…
Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where…
James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech…
Full service CRO Choice Pharma moved its operations from Europe to Asia in 2008, and since then the company has thrived. The managing director and business director for the company…
A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to “break out from the typical dilemma of ordinary biotech firms—to either engage…
The president of Pharmaceutical Industry Technology and Development Center (PITDC) considers the company’s need to remain an international competitor and how to achieve it, the gap in new drug development…
General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved…
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
The chairman of Taipei Medical University (TMU) discusses the key challenges TMU has faced over the years, how these challenges will continue to affect the future, and what international accreditation…
See our Cookie Privacy Policy Here